Literature DB >> 7239553

[Cyclosporin A--effects and side effects in the treatment of rheumatoid and psoriatic arthritis (author's transl)].

U Graf, U Marbet, W Müller, G Thiel.   

Abstract

The treatment of rheumatoid arthritis and psoriatic arthritis with cyclosporin A is described. Cyslosporin A is a new selective immunosuppressant which acts primarily on the T lymphocytes. It has already been shown to be effective in preventing rejection following kidney transplantation as well as in preventing graft-versus-host disease. In rheumatoid and psoriatic arthritis, however, its effect was not satisfactory, although rather different in the two conditions; overall only about one third of the patients showed any marked improvement. By contrast, and for reasons which are as yet unexplained, it had a beneficial effect on the cutaneous symptoms of psoriasis. Cyclosporin A had little effect on immune parameters. Side effects--mainly kidney toxicity, gastro-intestinal reactions and hirsutism--were common but reversible. On present evidence its principal indication among rheumatological diseases would seem to be as a treatment for severe, intractable psoriatic arthritis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7239553

Source DB:  PubMed          Journal:  Immun Infekt


  4 in total

1.  Assessment of efficacy and acceptability of low dose cyclosporin in patients with rheumatoid arthritis.

Authors:  M Dougados; L Duchesne; H Awada; B Amor
Journal:  Ann Rheum Dis       Date:  1989-07       Impact factor: 19.103

2.  Cyclosporin A (CyA) in primary Sjögren's syndrome: a double blind study.

Authors:  A A Drosos; F N Skopouli; J S Costopoulos; C S Papadimitriou; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  1986-09       Impact factor: 19.103

3.  Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients.

Authors:  M Dougados; H Awada; B Amor
Journal:  Ann Rheum Dis       Date:  1988-02       Impact factor: 19.103

4.  Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process.

Authors:  Arun Bhaskar; Alan Bell; Michael Boivin; Wellington Briques; Matthew Brown; Hance Clarke; Claude Cyr; Elon Eisenberg; Ricardo Ferreira de Oliveira Silva; Eva Frohlich; Peter Georgius; Malcolm Hogg; Tina Ingrid Horsted; Caroline A MacCallum; Kirsten R Müller-Vahl; Colleen O'Connell; Robert Sealey; Marc Seibolt; Aaron Sihota; Brennan K Smith; Dustin Sulak; Antonio Vigano; Dwight E Moulin
Journal:  J Cannabis Res       Date:  2021-07-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.